Ramelteon

DB00980

small molecule approved investigational

Deskripsi

Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse.

Struktur Molekul 2D

Berat 259.3434
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) ~1-2.6 hours
Volume Distribusi * 73.6 L
Klirens (Clearance) -

Absorpsi

Rapid, total absorption is at least 84%.

Metabolisme

Hepatic

Rute Eliminasi

Following oral administration of radiolabeled ramelteon, 84% of total radioactivity was excreted in urine and approximately 4% in feces, resulting in a mean recovery of 88%. Less than 0.1% of the dose was excreted in urine and feces as the parent compound.

Interaksi Makanan

2 Data
  • 1. Avoid alcohol.
  • 2. Do not take with or immediately after a high-fat meal.

Interaksi Obat

1666 Data
Deferasirox The serum concentration of Ramelteon can be increased when it is combined with Deferasirox.
Peginterferon alfa-2b The serum concentration of Ramelteon can be increased when it is combined with Peginterferon alfa-2b.
Leflunomide The serum concentration of Ramelteon can be decreased when it is combined with Leflunomide.
Teriflunomide The serum concentration of Ramelteon can be decreased when it is combined with Teriflunomide.
Buprenorphine Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.
Hydrocodone Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.
Magnesium sulfate The therapeutic efficacy of Ramelteon can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Ramelteon may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.
Mirtazapine Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.
Orphenadrine Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.
Pramipexole Ramelteon may increase the sedative activities of Pramipexole.
Ropinirole Ramelteon may increase the sedative activities of Ropinirole.
Rotigotine Ramelteon may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Ramelteon.
Suvorexant Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.
Thalidomide Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Dabrafenib The serum concentration of Ramelteon can be decreased when it is combined with Dabrafenib.
Luliconazole The serum concentration of Ramelteon can be increased when it is combined with Luliconazole.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Ramelteon.
Sodium oxybate Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Cyproterone acetate The metabolism of Ramelteon can be increased when combined with Cyproterone acetate.
Ethanol Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.
Citalopram The risk or severity of adverse effects can be increased when Ramelteon is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Ramelteon is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Ramelteon is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Ramelteon is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Ramelteon is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Ramelteon is combined with Sibutramine.
Escitalopram The risk or severity of adverse effects can be increased when Ramelteon is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Ramelteon is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Ramelteon is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Ramelteon is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Ramelteon is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Ramelteon is combined with Seproxetine.
Levomilnacipran Ramelteon may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Indalpine The risk or severity of adverse effects can be increased when Ramelteon is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Ramelteon is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Ramelteon is combined with Alaproclate.
Lumacaftor The serum concentration of Ramelteon can be decreased when it is combined with Lumacaftor.
Benzatropine Benzatropine may decrease the excretion rate of Ramelteon which could result in a higher serum level.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Ramelteon.
Amoxapine The risk or severity of CNS depression can be increased when Amoxapine is combined with Ramelteon.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Ramelteon.
Propantheline Propantheline may decrease the excretion rate of Ramelteon which could result in a higher serum level.
Dicyclomine Dicyclomine may decrease the excretion rate of Ramelteon which could result in a higher serum level.
Maprotiline The risk or severity of CNS depression can be increased when Maprotiline is combined with Ramelteon.
Tolterodine Ramelteon may decrease the excretion rate of Tolterodine which could result in a higher serum level.
Flavoxate Ramelteon may decrease the excretion rate of Flavoxate which could result in a higher serum level.
Tiotropium Ramelteon may decrease the excretion rate of Tiotropium which could result in a higher serum level.
Pizotifen The risk or severity of CNS depression can be increased when Ramelteon is combined with Pizotifen.
Fesoterodine Ramelteon may decrease the excretion rate of Fesoterodine which could result in a higher serum level.
Aclidinium Ramelteon may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Trimebutine Ramelteon may decrease the excretion rate of Trimebutine which could result in a higher serum level.
Imidafenacin Ramelteon may decrease the excretion rate of Imidafenacin which could result in a higher serum level.
Propiverine Ramelteon may decrease the excretion rate of Propiverine which could result in a higher serum level.
Quetiapine The risk or severity of CNS depression can be increased when Ramelteon is combined with Quetiapine.
Amitriptyline The risk or severity of CNS depression can be increased when Amitriptyline is combined with Ramelteon.
Doxepin The risk or severity of CNS depression can be increased when Ramelteon is combined with Doxepin.
Desipramine The risk or severity of CNS depression can be increased when Ramelteon is combined with Desipramine.
Nortriptyline The risk or severity of CNS depression can be increased when Nortriptyline is combined with Ramelteon.
Zopiclone The risk or severity of adverse effects can be increased when Ramelteon is combined with Zopiclone.
Albendazole The metabolism of Ramelteon can be increased when combined with Albendazole.
Carbamazepine The metabolism of Ramelteon can be increased when combined with Carbamazepine.
Primidone The metabolism of Ramelteon can be increased when combined with Primidone.
Caffeine The metabolism of Ramelteon can be decreased when combined with Caffeine.
Moxifloxacin The metabolism of Ramelteon can be decreased when combined with Moxifloxacin.
Lidocaine The metabolism of Ramelteon can be decreased when combined with Lidocaine.
Mexiletine The metabolism of Ramelteon can be decreased when combined with Mexiletine.
Alosetron The metabolism of Ramelteon can be decreased when combined with Alosetron.
Gatifloxacin The metabolism of Ramelteon can be decreased when combined with Gatifloxacin.
Simeprevir The metabolism of Ramelteon can be decreased when combined with Simeprevir.
Lobeglitazone The metabolism of Ramelteon can be decreased when combined with Lobeglitazone.
Pazufloxacin The metabolism of Ramelteon can be decreased when combined with Pazufloxacin.
Osilodrostat The metabolism of Ramelteon can be decreased when combined with Osilodrostat.
Ticlopidine The metabolism of Ramelteon can be decreased when combined with Ticlopidine.
Chloramphenicol The metabolism of Ramelteon can be decreased when combined with Chloramphenicol.
Lansoprazole The metabolism of Ramelteon can be decreased when combined with Lansoprazole.
Isoniazid The metabolism of Ramelteon can be decreased when combined with Isoniazid.
Miconazole The metabolism of Ramelteon can be decreased when combined with Miconazole.
Gemfibrozil The metabolism of Ramelteon can be decreased when combined with Gemfibrozil.
Imipramine The metabolism of Ramelteon can be decreased when combined with Imipramine.
Clomipramine The metabolism of Ramelteon can be decreased when combined with Clomipramine.
Zafirlukast The metabolism of Ramelteon can be decreased when combined with Zafirlukast.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Ramelteon.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Ramelteon.
Tryptophan The risk or severity of CNS depression can be increased when Tryptophan is combined with Ramelteon.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.

Target Protein

Melatonin receptor type 1B MTNR1B
Melatonin receptor type 1A MTNR1A

Referensi & Sumber

Synthesis reference: Vinod Kumar Kansal, Dhirenkumar N. Mistry, Sanjay L. Vasoya, "Intermediates and processes for the synthesis of Ramelteon." U.S. Patent US20080242877, issued October 02, 2008.
Artikel (PubMed)
  • PMID: 16432265
    Karim A, Tolbert D, Cao C: Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol. 2006 Feb;46(2):140-8.
  • PMID: 19228178
    Miyamoto M: Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther. 2009 Winter;15(1):32-51. doi: 10.1111/j.1755-5949.2008.00066.x.
  • PMID: 19568703
    Pandi-Perumal SR, Srinivasan V, Spence DW, Moscovitch A, Hardeland R, Brown GM, Cardinali DP: Ramelteon: a review of its therapeutic potential in sleep disorders. Adv Ther. 2009 Jun;26(6):613-26. doi: 10.1007/s12325-009-0041-6. Epub 2009 Jun 30.
  • PMID: 17157111
    Borja NL, Daniel KL: Ramelteon for the treatment of insomnia. Clin Ther. 2006 Oct;28(10):1540-55.
  • PMID: 16173650
    Roth T, Stubbs C, Walsh JK: Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep. 2005 Mar;28(3):303-7.
  • PMID: 18729542
    Simpson D, Curran MP: Ramelteon: a review of its use in insomnia. Drugs. 2008;68(13):1901-19.

Contoh Produk & Brand

Produk: 42 • International brands: 0
Produk
  • Ramelteon
    Tablet • 8 mg/1 • Oral • US • Generic • Approved
  • Ramelteon
    Tablet • 8 mg/1 • Oral • US • Generic • Approved
  • Ramelteon
    Tablet • 8 mg/1 • Oral • US • Generic • Approved
  • Ramelteon
    Tablet • 8 mg/1 • Oral • US • Generic • Approved
  • Ramelteon
    Tablet • 8 mg/1 • Oral • US • Generic • Approved
  • Ramelteon
    Tablet, film coated • 8 mg/1 • Oral • US • Generic • Approved
  • Ramelteon
    Tablet • 8 mg/1 • Oral • US • Generic • Approved
  • Ramelteon
    Tablet, film coated • 8 mg/1 • Oral • US • Generic • Approved
Menampilkan 8 dari 42 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul